DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study.
This study examined the possible association between the polymorphism in the dopamine receptor DRD4 gene and response to risperidone among 24 Israeli Jewish adolescent inpatients with first-episode schizophrenia. Response was categorically determined by a change of >40% on the Brief Psychiatric Rating Scale (BPRS). No significant association was found between the DRD4 genotype and clinical response, although carriers of <7 repeat alleles demonstrated higher response rate (10/20 vs. 0/4, P=0.11). Studies in larger groups of adolescent schizophrenia patients are warranted to clarify the possible association between DRD4 exon III repeat alleles and the response to risperidone.
Adolescent Inpatient Department, Geha Mental Health Center, Rabin Medical Center, Petach Tikva 49100, Israel. zalsman@post.tau.ac.il
Gil
G
Zalsman
Amos
A
Frisch
Shaul
S
Lev-Ran
Andrés
A
Martin
Elena
E
Michaelovsky
Daniela
D
Bensason
Doron
D
Gothelf
Eitan
E
Nahshoni
Samuel
S
Tyano
Abraham
A
Weizman
D000293:Adolescent; D000483:Alleles; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004247:DNA / Q000235:genetics; D005091:Exons / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D006801:Humans; D007557:Israel; D008297:Male; D010597:Pharmacogenetics; D010865:Pilot Projects; D011110:Polymorphism, Genetic / Q000235:genetics*; D011569:Psychiatric Status Rating Scales; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D050638:Receptors, Dopamine D4; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*
D014150:Antipsychotic Agents; C493599:DRD4 protein, human; D017448:Receptors, Dopamine D2; D050638:Receptors, Dopamine D4; D004247:DNA; D018967:Risperidone